Ketamine for chronic depression: two cautionary tales
Journal
Journal of psychiatry & neuroscience : JPN
ISSN: 1488-2434
Titre abrégé: J Psychiatry Neurosci
Pays: Canada
ID NLM: 9107859
Informations de publication
Date de publication:
01 Nov 2019
01 Nov 2019
Historique:
entrez:
2
10
2019
pubmed:
2
10
2019
medline:
23
6
2020
Statut:
ppublish
Résumé
A growing body of literature has shown the effectiveness of ketamine for treating chronic depression. How long the beneficial effects of repeated ketamine last once infusions are stopped, however, remains largely unknown. Understanding the challenges that ensue after ketamine cessation can help clinicians optimally guide patients who opt for ketamine treatment and minimize the associated risks. In this commentary, we discuss some unexpected data gathered from participants of a pilot study on the effects of adjunctive ketamine infusion for resistant depression.
Identifiants
pubmed: 31573153
doi: 10.1503/jpn.190073
pmc: PMC6821514
doi:
Substances chimiques
Excitatory Amino Acid Antagonists
0
Ketamine
690G0D6V8H
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
384-385Informations de copyright
© 2019 Joule Inc. or its licensors
Déclaration de conflit d'intérêts
P. Blier declares receiving honoraria from Janssen for participating on its advisory board, giving lectures and preparing educational material. He is also the site principal investigator for esketamine trials (Janssen). J. Talbot and J. Phillips declare no competing interests.
Références
Can J Psychiatry. 2016 Sep;61(9):540-60
pubmed: 27486148
Biol Psychiatry. 2013 Aug 15;74(4):250-6
pubmed: 22840761
Am J Psychiatry. 2019 May 1;176(5):401-409
pubmed: 30922101
JAMA Psychiatry. 2018 Feb 1;75(2):139-148
pubmed: 29282469
J Affect Disord. 2014 Feb;155:123-9
pubmed: 24268616
J Affect Disord. 2019 May 15;251:205-212
pubmed: 30927581
CNS Drugs. 2015 Mar;29(3):181-8
pubmed: 25715884
Am J Psychiatry. 2018 Feb 01;175(2):150-158
pubmed: 28969441
JAMA Psychiatry. 2017 Apr 1;74(4):399-405
pubmed: 28249076